NCT04970108

Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension

National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: EMS · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Egito association in the treatment of type 2 diabetes mellitus and hypertension

Conditions

• Hypertension Associated
• Type II Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Egito	EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
DRUG	Empagliflozin + telmisartan	Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.

Timeline

• Start date: 2023-08-01
• Primary completion: 2025-01-01
• Completion: 2025-05-01
• First posted: 2021-07-21
• Last updated: 2023-09-08